ELEVATION ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.83 USD | -0.26% |
|
+2.68% | +613.22% |
| 14/05 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
| 02/05 | Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Good evening. My name is Chad, and I will be y...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Calendar
13/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.83
USD
Average target price
7.8
USD
Spread / Average Target
+103.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +613.22% | 21Cr | |
| +9.83% | 12TCr | |
| +10.80% | 11TCr | |
| -10.84% | 2.34TCr | |
| -1.69% | 2.21TCr | |
| -10.23% | 1.83TCr | |
| -41.92% | 1.66TCr | |
| -15.11% | 1.6TCr | |
| +6.62% | 1.4TCr | |
| +17.53% | 1.17TCr |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Transcript : Elevation Oncology, Inc. - Special Call
